Waddle Mark R, Ko Stephen J, May Jackson, Kaleem Tasneem, Miller Daniel H, Stross William C, Malouff Timothy D, Wert Katey, Cuthbert Kristin, Landy Robin, Strong Gerald, Vallow Laura A, Johnson Margaret M
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States.
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States.
Lung Cancer. 2020 Oct;148:79-85. doi: 10.1016/j.lungcan.2020.07.036. Epub 2020 Aug 7.
Low dose computerized tomography (LDCT) has been shown to reduce lung cancer specific mortality by 20 %. Despite U.S. Preventive Services Task Force (USPSTF) endorsement, screening of appropriate patients in the U.S. remains low, at 1.9 %. The goal of this study was to assess the number and type of patients that would qualify for lung cancer screening based upon recommendations by various guidelines.
We prospectively collected a patient reported questionnaire, including smoking history, family history, exposure history, and demographics, from April-October 2017 from new consults in the Department of Radiation Oncology and Otolaryngology (ORL). Patients smoking status and patient factors were collected and reported. Patients qualifying for screening by USPSTF, the National Comprehensive Cancer Network (NCCN), and Tammemagi scoring criteria were identified. Multivariate analysis assessed the factors associated with positive criteria for screening and the sensitivity of each criterion was calculated.
There were 546 new consults during the study period and 528 successfully completed the questionnaire. A total of 104/528 (20 %) patients who completed questionnaires qualified for screening based on any guideline. After exclusion of active lung cancer (n = 19), poor prognosis (n = 24), and CT as part of surveillance (n = 16), 45 (8.5 %) patients would require LDCT. Of the entire population, 10 %, 11 % and 18 % of patients qualified based on USPSTF, NCCN, and Tammemagi, which was reduced to 4.9 %, 5.3 %, and 7.8 %, respectively after exclusions. Patients with head and neck cancer (40 %), skin cancer (27 %), and prostate cancer (11 %) accounted for the majority of patients eligible for screening after exclusions. The sensitivity of the USPSTF, NCCN, and Tammemagi criteria in patients with a diagnosis of lung cancer (n = 26) was 38.5 % (CI 20.2 %-59.4 %), 46.2 % (CI 26.6 %-66.6 %), and 61.5 % (CI 40.6 %-79.8 %), respectively.
We successfully identified 9 % of an oncology population at consultation who could benefit from lung cancer screening in survivorship. Distribution of a written or electronic questionnaire at consultation is a simple, low cost, effective method of identifying patients who would benefit from LDCT.
低剂量计算机断层扫描(LDCT)已被证明可将肺癌特异性死亡率降低20%。尽管美国预防服务工作组(USPSTF)表示认可,但在美国,对合适患者的筛查率仍然很低,仅为1.9%。本研究的目的是根据各种指南的建议,评估符合肺癌筛查条件的患者数量和类型。
我们前瞻性地收集了一份患者报告问卷,包括吸烟史、家族史、接触史和人口统计学信息,于2017年4月至10月从放射肿瘤学和耳鼻喉科(ORL)的新咨询患者中获取。收集并报告了患者的吸烟状况和患者因素。确定了符合USPSTF、美国国立综合癌症网络(NCCN)和塔梅马吉评分标准筛查条件的患者。多变量分析评估了与筛查阳性标准相关的因素,并计算了每个标准的敏感性。
研究期间共有546例新咨询患者,528例成功完成问卷。共有104/528(20%)完成问卷的患者符合任何指南的筛查条件。排除活动性肺癌患者(n = 19)、预后不良患者(n = 24)以及作为监测一部分的CT检查患者(n = 16)后,45例(8.5%)患者需要进行LDCT检查。在整个人口中,分别有10%、11%和18%的患者符合USPSTF、NCCN和塔梅马吉标准,排除后分别降至4.9%、5.3%和7.8%。排除后,头颈部癌患者(40%)、皮肤癌患者(27%)和前列腺癌患者(11%)占符合筛查条件患者的大多数。USPSTF、NCCN和塔梅马吉标准在肺癌诊断患者(n = 26)中的敏感性分别为38.5%(CI 20.2%-59.4%)、46.2%(CI 26.6%-66.6%)和61.5%(CI 40.6%-79.8%)。
我们成功识别出9%的肿瘤咨询患者,他们在生存期间可从肺癌筛查中获益。在咨询时发放书面或电子问卷是一种简单、低成本、有效的识别可从LDCT中获益患者的方法。